Perfusion Imaging, Spectroscopy, and Advanced MR

Perfusion imaging quantifies tissue blood flow and helps separate infarct core (already-dead tissue) from ischemic penumbra (at-risk but salvageable). This is the central physiological question in extended-window thrombectomy and tPA decisions. CT perfusion (CTP), dynamic susceptibility contrast MR (DSC-MR), and arterial spin labeling (ASL) all generate perfusion maps with different strengths.

🔹 Bottom Line: Perfusion Imaging

  • CT perfusion (CTP): workhorse for acute stroke triage; fast and widely available. Generates CBF, CBV, MTT, Tmax maps.
  • DSC-MR perfusion: dynamic susceptibility contrast; brain tumor characterization (relative CBV high in high-grade glioma); also used for stroke.
  • ASL (arterial spin labeling): no contrast required; quantifies CBF directly; useful in pediatric, renal-failure, or follow-up.
  • Stroke decision-making (DEFUSE / DAWN): core volume + penumbra mismatch defines extended-window thrombectomy eligibility (6–24 hours).
  • Core map: CBF <30% of contralateral (most labs). Penumbra: Tmax >6 sec.
  • MR spectroscopy: NAA down (neuronal loss), choline up (cell turnover), lactate up (anaerobic), lipid up (necrosis). Tumor grading + radiation necrosis vs recurrence.

Perfusion Parameters

  • CBV (cerebral blood volume): volume of blood per unit brain tissue (mL/100g). Falls in irreversible infarct core; preserved in penumbra (autoregulation).
  • CBF (cerebral blood flow): rate of blood delivery (mL/100g/min). Falls in core; reduced in penumbra.
  • MTT (mean transit time): average time blood spends in capillary bed. Prolonged in both core and penumbra.
  • Tmax: time to maximum of the residue function. Sensitive to bolus delay/dispersion — prolonged in penumbra and stenosis. Most widely used penumbra marker.
  • TTP (time to peak): similar to Tmax; older parameter; less robust to delay.

CT Perfusion (CTP)

Use

  • Acute stroke triage — extended-window thrombectomy (DAWN, DEFUSE-3) and selected tPA decisions.
  • Vasospasm monitoring post-SAH.
  • Cerebrovascular reserve assessment (with acetazolamide challenge).

Acquisition

  • Dynamic acquisition during iodinated contrast bolus.
  • ~45–60 second scan covers a brain volume.
  • Generates CBV, CBF, MTT, Tmax maps automatically (RAPID, Olea, Brainomix, vendor packages).

Core / Penumbra Definition

Tissue Definition (RAPID)
Infarct core CBF <30% of contralateral
Penumbra (hypoperfused at-risk) Tmax >6 seconds
Mismatch volume Penumbra − Core
Mismatch ratio Penumbra / Core

DAWN / DEFUSE-3 Criteria (Extended-Window Thrombectomy)

  • DAWN (6–24 hours):
    • NIHSS ≥10 + core <31 mL (age ≥80) OR core <51 mL (age <80).
    • NIHSS ≥20 + core <51 mL (age <80).
  • DEFUSE-3 (6–16 hours):
    • Core <70 mL + mismatch ratio ≥1.8 + mismatch volume ≥15 mL.

Pitfalls

  • Bolus timing errors: too early/too late bolus skews maps.
  • Motion artifact compromises perfusion maps significantly.
  • Cardiac output low: prolongs all transit parameters globally.
  • Atrial fibrillation: bolus dispersion distorts maps.
  • Old infarct in same territory: confounds core measurement.
  • Posterior fossa: bone artifact + small volumes limit accuracy.
  • Radiation dose: cumulative concern if multiple studies.
  • Contrast nephropathy: risk in CKD.

DSC-MR Perfusion

Use

  • Brain tumor characterization: relative CBV (rCBV) elevated in high-grade glioma; distinguishes recurrence from radiation necrosis.
  • Stroke: where MRI is preferred over CT (pediatric, repeated assessment).
  • Lymphoma vs glioma: lymphoma has lower rCBV than glioma despite high cellularity.

Acquisition

  • Dynamic susceptibility contrast: gadolinium bolus + rapid T2*-weighted EPI imaging.
  • Generates rCBV, rCBF, MTT maps.

Pitfalls

  • Susceptibility artifacts near skull base, sinuses, prior surgery.
  • Leakage correction required for enhancing lesions (especially gliomas, metastases).
  • Gadolinium contrast required.

Arterial Spin Labeling (ASL)

Use

  • Contrast-free perfusion imaging (magnetically labels arterial water as endogenous tracer).
  • Pediatric (no contrast).
  • Repeated assessments / cerebrovascular reserve testing.
  • Stroke / cerebrovascular disease.
  • Neurodegenerative disease research (regional hypoperfusion patterns).

Pitfalls

  • Lower SNR than DSC-MR.
  • Bolus arrival time variability in older / atherosclerotic patients can produce ATA (arterial transit artifact).
  • Lower-flow regions hard to quantify reliably.

MR Spectroscopy (MRS)

Use

  • Metabolic profile of a voxel.
  • Tumor grade prediction: high choline / NAA ratio + lipid/lactate peaks suggest high grade.
  • Radiation necrosis vs recurrence: necrosis has flat metabolic profile; recurrence has elevated choline.
  • Mitochondrial disease: elevated lactate in MELAS, Leigh.
  • Leukodystrophies: NAA changes; some specific patterns (NAA elevation in Canavan, NAA depletion in MLD).
  • Hepatic encephalopathy: elevated glutamine-glutamate (Glx); reduced myo-inositol.
  • Demyelination: NAA reduction in active plaques.

Key Metabolites

Peak (ppm) Metabolite Meaning
2.0 N-acetyl aspartate (NAA) Neuronal density (decreased in neuronal loss)
3.0 Creatine (Cr) Energy metabolism (relatively stable — internal reference)
3.2 Choline (Cho) Cell membrane turnover (elevated in tumors, demyelination)
3.5 Myo-inositol (mI) Glial marker; elevated in Alzheimer; reduced in hepatic encephalopathy
1.3 (doublet, inverts on long TE) Lactate Anaerobic metabolism; mitochondrial disease, infarct, abscess
0.9–1.4 Lipid Necrosis; high-grade tumor
2.0–2.5 Glutamate / glutamine (Glx) Hepatic encephalopathy; epilepsy; some neurodegenerative
2.4 2-hydroxyglutarate (2HG) IDH-mutant glioma (specific!)

Diffusion Tensor Imaging (DTI) and Tractography

  • DTI measures water diffusion directionality (anisotropy) — high in white matter tracts.
  • Generates fractional anisotropy (FA) and apparent diffusion coefficient maps.
  • Tractography reconstructs white matter pathways from DTI data.
  • Uses: presurgical planning (corticospinal tract, language tracts), MS lesion characterization, TBI (diffuse axonal injury), pediatric leukodystrophy research, schizophrenia / psychiatric research.
  • Not yet a routine clinical diagnostic test; widely used for surgical planning + research.

Functional MRI (fMRI)

  • BOLD (blood oxygen level dependent) signal — neural activity → local hyperemia → signal change.
  • Task-based fMRI: patient performs task during scan; activated regions identified.
  • Resting-state fMRI: spontaneous correlated networks (default mode, attention, language).
  • Clinical use: presurgical mapping of motor, language, memory.
  • Limitation: motion-sensitive; cannot replace intraoperative cortical stimulation for definitive language mapping.

🔹 Clinical Relevance: When Perfusion / Advanced MR Changes Decisions

  • Acute stroke, 6–24 hours from onset: CTP for DAWN / DEFUSE-3 criteria — if mismatch present, thrombectomy benefits.
  • Acute stroke, unknown onset (wake-up): DWI-FLAIR mismatch on MRI identifies treatable window for tPA (WAKE-UP trial); CTP can also identify penumbra.
  • Brain tumor characterization: DSC-MR + spectroscopy distinguish high-grade vs low-grade glioma, recurrence vs radiation necrosis, lymphoma vs glioma.
  • Suspected IDH-mutant glioma: 2-hydroxyglutarate peak on spectroscopy is highly specific.
  • Presurgical epilepsy planning: fMRI for language + memory lateralization; DTI for corticospinal / Meyer loop visualization.
  • Pediatric or contrast-contraindicated: ASL provides perfusion without contrast.
  • Vasospasm post-SAH: CTP detects asymptomatic perfusion deficits before clinical decline.
  • Suspected mitochondrial / hepatic / leukodystrophic: targeted MR spectroscopy.

Pitfalls and Pearls

  • Core volume on CTP is an estimate: bolus dispersion in cardiac dysfunction, AFib, or low cardiac output inflates “core” — confirm with DWI when possible.
  • RAPID output is widely used but vendor-specific: thresholds may not transfer directly between platforms.
  • Motion ruins CTP: a single 1-second movement can void the study.
  • Tmax >6 sec is the consensus penumbra threshold; stricter (Tmax >10) defines severely hypoperfused.
  • DSC-MR requires leakage correction for enhancing lesions — uncorrected maps overestimate rCBV.
  • ASL is degraded by atrial arrival time variability in atherosclerotic patients.
  • Spectroscopy lipid peak = necrosis (suggests high-grade tumor / radiation necrosis); lactate peak = anaerobic metabolism (mitochondrial, infarct, abscess).
  • 2HG peak on spectroscopy is highly specific for IDH-mutant glioma.
  • fMRI cannot replace intraoperative cortical stimulation for definitive language mapping in epilepsy / tumor surgery.
  • DAWN criteria require both NIHSS threshold AND core volume threshold — don’t quote them loosely.

References

  1. Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct (DAWN). N Engl J Med. 2018;378(1):11-21.
  2. Albers GW, Marks MP, Kemp S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging (DEFUSE-3). N Engl J Med. 2018;378(8):708-718.
  3. Bivard A, Levi C, Spratt N, Parsons M. Perfusion CT in acute stroke: a comprehensive analysis of infarct and penumbra. Radiology. 2013;267(2):543-550.
  4. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol. 2003;24(10):1989-1998.
  5. Choi C, Ganji SK, DeBerardinis RJ, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med. 2012;18(4):624-629.